{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:18:38Z","timestamp":1785525518627,"version":"3.56.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ccm.2018.07.008","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T12:02:24Z","timestamp":1541073744000},"page":"753-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Adjunctive Therapies for Community-Acquired Pneumonia"],"prefix":"10.1016","volume":"39","author":[{"given":"Adrian","family":"Ceccato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Barbeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9998","key":"10.1016\/j.ccm.2018.07.008_bib1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","article-title":"Community-acquired pneumonia","volume":"386","author":"Prina","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ccm.2018.07.008_bib2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ccm.2018.07.008_bib3","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1164\/rccm.201611-2262OC","article-title":"New sepsis definition (Sepsis-3) and community-acquired pneumonia mortality: a validation and clinical decision-making study","volume":"196","author":"Ranzani","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2018.07.008_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/596307","article-title":"Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America\/American Thoracic Society guidelines to predict an intensive care unit admission","volume":"48","author":"Liapikou","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"25","key":"10.1016\/j.ccm.2018.07.008_bib5","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMp1113569","article-title":"The burden of disease and the changing task of medicine","volume":"366","author":"Jones","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccm.2018.07.008_bib6","doi-asserted-by":"crossref","first-page":"567.e1-7","DOI":"10.1016\/j.cmi.2016.03.015","article-title":"Declining mortality among hospitalized patients with community-acquired pneumonia","volume":"22","author":"Simonetti","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.ccm.2018.07.008_bib7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(15)00151-6","article-title":"Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study","volume":"15","author":"Shindo","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.ccm.2018.07.008_bib8","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/498119","article-title":"Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival","volume":"41","author":"Bod\u00ed","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2018.07.008_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1183\/09031936.00152514","article-title":"Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis","volume":"45","author":"Torres","year":"2015","journal-title":"Eur Respir J"},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2018.07.008_bib10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2018.07.008_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/17476348.2016.1240037","article-title":"Clinical management of community acquired pneumonia in the elderly patient","author":"Cilloniz","year":"2016","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1378\/chest.13-0062","article-title":"Impact of age and comorbidity on cause and outcome in community-acquired pneumonia","volume":"144","author":"Cill\u00f3niz","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ccm.2018.07.008_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/thx.2007.086785","article-title":"Markers of treatment failure in hospitalised community acquired pneumonia","volume":"63","author":"Men\u00e9ndez","year":"2008","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.ccm.2018.07.008_bib14","first-page":"419","article-title":"Pneumonia presenting with organ dysfunctions: causative microorganisms, host factors and outcome","volume":"73","author":"Men\u00e9ndez","year":"2016","journal-title":"J\u00a0Infect"},{"issue":"7","key":"10.1016\/j.ccm.2018.07.008_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jama.2015.115","article-title":"Corticosteroids for severe community-acquired pneumonia: not for everyone","volume":"313","author":"Wunderink","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ccm.2018.07.008_bib16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/thx.2003.017756","article-title":"Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome","volume":"59","author":"Men\u00e9ndez","year":"2004","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.ccm.2018.07.008_bib17","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s10753-014-9840-2","article-title":"Contrasting inflammatory responses in severe and non-severe community-acquired pneumonia","volume":"37","author":"Fernandez-Botran","year":"2014","journal-title":"Inflammation"},{"issue":"15","key":"10.1016\/j.ccm.2018.07.008_bib18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/archinte.167.15.1655","article-title":"Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and inflammatory markers of sepsis (GenIMS) study","volume":"167","author":"Kellum","year":"2007","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-0032-1315638","article-title":"Biomarkers and community-acquired pneumonia: tailoring management with biological data","volume":"33","author":"Torres","year":"2012","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2018.07.008_bib20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1183\/09031936.00060112","article-title":"Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia","volume":"41","author":"Paats","year":"2013","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ccm.2018.07.008_bib21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2018.07.008_bib22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"2 Suppl","key":"10.1016\/j.ccm.2018.07.008_bib23","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/CCM.0b013e3181c98d21","article-title":"Inflammation and coagulation","volume":"38","author":"Levi","year":"2010","journal-title":"Crit Care Med"},{"issue":"7 Suppl","key":"10.1016\/j.ccm.2018.07.008_bib24","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/00003246-200107001-00016","article-title":"Hepatic response to sepsis: interaction between coagulation and inflammatory processes","volume":"29","author":"Dhainaut","year":"2001","journal-title":"Crit Care Med"},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2018.07.008_bib25","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0049-3848(10)70153-5","article-title":"Inflammation and coagulation. An overview","volume":"127","author":"Pet\u00e4j\u00e4","year":"2011","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0037-1617143","article-title":"The coagulant response in sepsis and inflammation","volume":"30","author":"Levi","year":"2010","journal-title":"Hamostaseologie"},{"issue":"8","key":"10.1016\/j.ccm.2018.07.008_bib27","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1097\/00003246-200208000-00018","article-title":"Oxidative stress in critically ill patients with systemic inflammatory response syndrome","volume":"30","author":"Alonso de Vega","year":"2002","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccm.2018.07.008_bib28","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","article-title":"ROS function in redox signaling and oxidative stress","volume":"24","author":"Schieber","year":"2014","journal-title":"Curr Biol"},{"issue":"7","key":"10.1016\/j.ccm.2018.07.008_bib29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00003246-200301000-00022","article-title":"Adrenal insufficiency during septic shock","volume":"31","author":"Marik","year":"2003","journal-title":"Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccm.2018.07.008_bib31","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1097\/CCM.0000000000002737","article-title":"Guidelines for the diagnosis and management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in critically Ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017","volume":"45","author":"Annane","year":"2017","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/CCM.0000000000002840","volume":"46","author":"Pastores","year":"2018","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2018.07.008_bib33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00134-005-0046-9","article-title":"Cortisol levels in patients with severe community-acquired pneumonia","volume":"32","author":"Salluh","year":"2006","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ccm.2018.07.008_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ebiom.2017.09.023","article-title":"Lymphopenic Community Acquired Pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality","volume":"24","author":"Bermejo-Martin","year":"2017","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.ccm.2018.07.008_bib35","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2213-2600(17)30444-7","article-title":"Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia","volume":"5","author":"Bermejo-Martin","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib36","doi-asserted-by":"crossref","first-page":"e000152","DOI":"10.1136\/bmjresp-2016-000152","article-title":"Serum levels of immunoglobulins and severity of community-acquired pneumonia","volume":"3","author":"de la Torre","year":"2016","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.ccm.2018.07.008_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcrc.2016.05.005","article-title":"IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia","volume":"35","author":"de la Torre","year":"2016","journal-title":"J\u00a0Crit Care"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13613-017-0268-3","article-title":"The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure","volume":"7","author":"Martin-Loeches","year":"2017","journal-title":"Ann Intensive Care"},{"issue":"8","key":"10.1016\/j.ccm.2018.07.008_bib39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ccm.2018.07.008_bib40","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ccm.2018.07.008_bib41","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.ccm.2018.07.008_bib42","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2014.4304","article-title":"Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia","volume":"311","author":"Mortensen","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ccm.2018.07.008_bib45","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Martin-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2018.07.008_bib46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1164\/rccm.200311-1578OC","article-title":"Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia","volume":"170","author":"Baddour","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijantimicag.2007.08.001","article-title":"Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators","volume":"31","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib48","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jac\/dkr520","article-title":"Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review","volume":"67","author":"Kovaleva","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.ccm.2018.07.008_bib49","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"14","key":"10.1016\/j.ccm.2018.07.008_bib50","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9782","key":"10.1016\/j.ccm.2018.07.008_bib51","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(11)60607-7","article-title":"Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial","volume":"377","author":"Meijvis","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1164\/rccm.200406-808OC","article-title":"Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study","volume":"171","author":"Confalonieri","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2018.07.008_bib53","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.200905-0808OC","article-title":"Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial","volume":"181","author":"Snijders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2018.07.008_bib54","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1183\/09031936.00027607","article-title":"Effects of systemic steroids in patients with severe community-acquired pneumonia","volume":"30","author":"Garcia-Vidal","year":"2007","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2018.07.008_bib55","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/cc10103","article-title":"Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial","volume":"15","author":"Fern\u00e1ndez-Serrano","year":"2011","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.ccm.2018.07.008_bib56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial","volume":"313","author":"Torres","year":"2015","journal-title":"JAMA"},{"issue":"9977","key":"10.1016\/j.ccm.2018.07.008_bib57","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(14)62447-8","article-title":"Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"385","author":"Blum","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccm.2018.07.008_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4236\/pp.2011.22009","article-title":"Corticosteroids and ICU course of community acquired pneumonia in\u00a0Egyptian settings","volume":"2","author":"Sabry","year":"2011","journal-title":"Pharmacol Pharm"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejcdt.2013.03.009","article-title":"Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia","volume":"62","author":"Nafae","year":"2013","journal-title":"Egypt J Chest Dis Tuberc"},{"issue":"7","key":"10.1016\/j.ccm.2018.07.008_bib60","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/M15-0715","article-title":"Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis","volume":"163","author":"Siemieniuk","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1378\/chest.15-1733","article-title":"Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis","volume":"149","author":"Wan","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2018.07.008_bib62","doi-asserted-by":"crossref","first-page":"14061","DOI":"10.1038\/srep14061","article-title":"Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and\u00a0meta-analysis 2015 update","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib63","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/cid\/cix801","article-title":"Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis","volume":"66","author":"Briel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2018.07.008_bib64","article-title":"Corticosteroids for pneumonia","volume":"12","author":"Stern","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2018.07.008_bib65","article-title":"Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis","author":"Wu","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"11","key":"10.1016\/j.ccm.2018.07.008_bib66","doi-asserted-by":"crossref","first-page":"e0165942","DOI":"10.1371\/journal.pone.0165942","article-title":"Efficacy and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: an updated systematic review and meta-analysis","volume":"11","author":"Bi","year":"2016","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.ccm.2018.07.008_bib67","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.2016.14799","article-title":"Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial","volume":"316","author":"Keh","year":"2016","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ccm.2018.07.008_bib68","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1001\/jama.2009.815","article-title":"Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review","volume":"301","author":"Annane","year":"2009","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ccm.2018.07.008_bib69","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"Venkatesh","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2018.07.008_bib70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa071366","article-title":"Hydrocortisone therapy for patients with septic shock","volume":"358","author":"Sprung","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2018.07.008_bib71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1183\/09031936.00081514","article-title":"Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients","volume":"45","author":"Tagami","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib72","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ccm.2018.07.008_bib73","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"3","author":"Rodrigo","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2018.07.008_bib74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13054-015-0764-5","article-title":"Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis","volume":"19","author":"Zhang","year":"2015","journal-title":"Crit Care"},{"issue":"10","key":"10.1016\/j.ccm.2018.07.008_bib75","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.cmi.2015.06.022","article-title":"Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis","volume":"21","author":"Yang","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ccm.2018.07.008_bib76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13054-016-1230-8","article-title":"The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness","volume":"20","author":"Delaney","year":"2016","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.ccm.2018.07.008_bib77","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1183\/13993003.00474-2016","article-title":"Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia","volume":"48","author":"Wirz","year":"2016","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.ccm.2018.07.008_bib78","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1007\/s00125-016-4091-4","article-title":"Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients","volume":"59","author":"Popovic","year":"2016","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.ccm.2018.07.008_bib79","doi-asserted-by":"crossref","first-page":"e0178022","DOI":"10.1371\/journal.pone.0178022","article-title":"Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: a post-hoc exploratory analysis of a randomized controlled trial","volume":"12","author":"Ceccato","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ccm.2018.07.008_bib80","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.chest.2016.11.036","article-title":"Hydrocortisone, Vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study","volume":"151","author":"Marik","year":"2017","journal-title":"Chest"},{"issue":"17","key":"10.1016\/j.ccm.2018.07.008_bib81","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1089\/ars.2013.5401","article-title":"Evaluation of vitamin C for adjuvant sepsis therapy","volume":"19","author":"Wilson","year":"2013","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"10.1016\/j.ccm.2018.07.008_bib82","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00003246-199603000-00006","article-title":"Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk","volume":"24","author":"Borrelli","year":"1996","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ccm.2018.07.008_bib83","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-12-32","article-title":"Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis","volume":"12","author":"Fowler","year":"2014","journal-title":"J\u00a0Transl Med"},{"issue":"6","key":"10.1016\/j.ccm.2018.07.008_bib84","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/CCM.0000000000001684","article-title":"\u201cVitamin S\u201d (Steroids) and Vitamin C for the treatment of severe sepsis and septic shock!","volume":"44","author":"Marik","year":"2016","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccm.2018.07.008_bib85","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccm.2018.07.008_bib86","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/rccm.201211-2020OC","article-title":"Recombinant human activated protein C for adults with septic shock: a randomized controlled trial","volume":"187","author":"Annane","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"10.1016\/j.ccm.2018.07.008_bib87","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2018.07.008_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004388.pub5","article-title":"Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients","volume":"12","author":"Mart\u00ed-Carvajal","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.ccm.2018.07.008_bib89","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1164\/rccm.201007-1167OC","article-title":"Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial","volume":"183","author":"Wunderink","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2018.07.008_bib90","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00134-013-2822-2","article-title":"Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis","volume":"39","author":"Yamakawa","year":"2013","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2018.07.008_bib91","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1160\/TH15-12-0987","article-title":"Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study","volume":"115","author":"Hayakawa","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ccm.2018.07.008_bib92","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13054-015-0810-3","article-title":"Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis","volume":"19","author":"Yoshimura","year":"2015","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.ccm.2018.07.008_bib93","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1378\/chest.111.4.1094","article-title":"Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe pneumonia: a pilot study","volume":"111","author":"Ferrer","year":"1997","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2018.07.008_bib94","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00134-015-4139-9","article-title":"Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination?","volume":"42","author":"Falcone","year":"2016","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib95","doi-asserted-by":"crossref","first-page":"e001595","DOI":"10.1161\/JAHA.114.001595","article-title":"Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin","volume":"4","author":"Falcone","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.ccm.2018.07.008_bib96","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.201209-1718OC","article-title":"A\u00a0multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis","volume":"187","author":"Kruger","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib97","doi-asserted-by":"crossref","first-page":"e006251","DOI":"10.1136\/bmjopen-2014-006251","article-title":"The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Viasus","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.ccm.2018.07.008_bib98","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.CCM.0000048629.32625.5D","article-title":"Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis","volume":"31","author":"Root","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ccm.2018.07.008_bib99","article-title":"Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock","volume":"9","author":"Alejandria","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.ccm.2018.07.008_bib100","first-page":"2677","article-title":"Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock","volume":"35","author":"Kreymann","year":"2007","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2018.07.008_bib101","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cmi.2016.01.021","article-title":"Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins","volume":"22","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.ccm.2018.07.008_bib102","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.rmed.2015.03.008","article-title":"Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - the CIGMA study","volume":"109","author":"Welte","year":"2015","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2018.07.008_bib103","doi-asserted-by":"crossref","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis"},{"issue":"9","key":"10.1016\/j.ccm.2018.07.008_bib104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4252\/wjsc.v8.i9.268","article-title":"Immunomodulation by mesenchymal stem cells: interplay between mesenchymal stem cells and regulatory lymphocytes","volume":"8","author":"Ma","year":"2016","journal-title":"World J Stem Cells"},{"key":"10.1016\/j.ccm.2018.07.008_bib105","first-page":"394917","article-title":"Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications","volume":"2015","author":"Castro-Manrreza","year":"2015","journal-title":"J\u00a0Immunol Res"},{"issue":"7","key":"10.1016\/j.ccm.2018.07.008_bib106","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1164\/rccm.201206-0990OC","article-title":"Therapeutic effects of human mesenchymal stem cells in ex\u00a0vivo human lungs injured with live bacteria","volume":"187","author":"Lee","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2018.07.008_bib107","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pupt.2017.03.005","article-title":"Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy","volume":"44","author":"Trabattoni","year":"2017","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027252311830087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027252311830087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:55:29Z","timestamp":1759452929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027252311830087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S027252311830087X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2018.07.008","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive Therapies for Community-Acquired Pneumonia","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2018.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}